Lebrikizumab
- Generic Name
- Lebrikizumab
- Brand Names
- Ebglyss
- Drug Type
- Biotech
- CAS Number
- 953400-68-5
- Unique Ingredient Identifier
- U9JLP7V031
- Background
Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 310
- Registration Number
- NCT05735483
- Locations
- 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇨🇦DermEdge Research, Mississauga, Ontario, Canada
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic DermatitisEczema
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT05559359
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Wright State Physicians, Fairborn, Ohio, United States
🇦🇷Centro de Investigaciones Metabólicas (CINME), Ciudad Autónoma de Buenos Aires, Argentina
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT05372419
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Wallace Medical Group, Inc., Los Angeles, California, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 86
- Registration Number
- NCT05369403
- Locations
- 🇺🇸
Direct Helpers Research Center, Hialeah, Florida, United States
🇺🇸Skin Care Physicians of Georgia, Macon, Georgia, United States
🇺🇸Miami Dermatology and Laser Research, Miami, Florida, United States
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
- Conditions
- Dermatitis, AtopicEczema
- Interventions
- Drug: Lebrikizumab-matching Placebo
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 331
- Registration Number
- NCT05149313
- Locations
- 🇫🇷
Alm Site 12, Reims, France
🇳🇱Alm Site 35, Utrecht, Netherlands
🇫🇷Alm Site 19, Lille, France
A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 242
- Registration Number
- NCT04840901
- Locations
- 🇺🇸
QPS, Springfield, Missouri, United States
🇺🇸LabCorp CRU, Inc., Madison, Wisconsin, United States
🇺🇸Covance Dallas, Dallas, Texas, United States
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- DermatitisDermatitis, AtopicSkin DiseasesSkin Diseases, GeneticEczema
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 286
- Registration Number
- NCT04760314
- Locations
- 🇯🇵
Hiroshima University Hospital, Hiroshima-shi, Hiroshima-ken, Japan
🇯🇵KAJI Dermatology Clinic, Nonoichi-shi, Ishikawa, Japan
🇯🇵Kosugi Dermatology Clinic, Kawasaki, Kanagawa, Japan
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 254
- Registration Number
- NCT04626297
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Modern Research Associates, Dallas, Texas, United States
🇺🇸Premier Clinical Research, Spokane, Washington, United States
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1153
- Registration Number
- NCT04392154
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Modern Research Associates, Dallas, Texas, United States
🇺🇸Paddington Testing Company Inc, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 309
- Registration Number
- NCT02546700
- Locations
- 🇺🇸
Centex Studies, Houston, Texas, United States
🇺🇸Comprehensive Clinical Research Inc., Berlin, New Jersey, United States
🇺🇸Clinical Research Inst. of Southern Oregon, Pc, Medford, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.